Last reviewed · How we verify
NCT07502677
Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral Sclerosis
trial testing SleepImage in Amyotrophic Lateral Sclerosis in 15 participants. Currently enrolling.
1 September 2026
Quick facts
| Lead sponsor | Royal Brompton & Harefield NHS Foundation Trust |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 15 |
| Start date | 24 March 2026 |
| Primary completion | 1 September 2026 |
| Estimated completion | 24 March 2027 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- SleepImage
Conditions studied
- Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →
Sponsor
Royal Brompton & Harefield NHS Foundation Trust
Who can join
18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The specific aim of this study is to try to discover the diagnostic accuracy of SleepImage technology for detecting respiratory failure in patients with MND. Importantly, this research project is not about NIV, it is about what method can most efficiently decide when to start NIV. To do this we'd like to collect data about you and your breathing from the SleepImage device when you come in for your routine overnight sleep study. We will compare this against the data that we would collect anyway.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07502677
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Amyotrophic Lateral Sclerosis
Currently open trials in the same condition.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07204977 — Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS) · Phase 1 · active not recruiting
- NCT07290062 — A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants · Phase 1 · recruiting
- NCT07259980 — A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD- · recruiting
- NCT07287397 — Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS · Phase 1, PHASE2 · recruiting
Other Royal Brompton & Harefield NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07498842 — Corticosteroid Tapering in Sarcoidosis · NA · recruiting
- NCT07402434 — A Prospective Study of Advanced Diagnostics in People With an Unclear Diagnosis of Cystic Fibrosis · not yet recruiting
- NCT06661278 — Evaluation of Exercise Testing and Physical Activity in Children and Adolescents Living With Inherited Arrhythmias · recruiting
- NCT06519240 — A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection. · NA · not yet recruiting
- NCT06397833 — A Prospective, Observational, Single Centre Study to Assess the Feasibility of the Data Harvested by the Acorai Intracar · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07502677 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Brompton & Harefield NHS Foundation Trust
- Last refreshed: 31 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07502677.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing